U.S. markets open in 4 hours 24 minutes
  • S&P Futures

    3,654.75
    -5.75 (-0.16%)
     
  • Dow Futures

    29,705.00
    -99.00 (-0.33%)
     
  • Nasdaq Futures

    12,444.00
    -8.25 (-0.07%)
     
  • Russell 2000 Futures

    1,831.80
    -3.70 (-0.20%)
     
  • Crude Oil

    44.70
    +0.15 (+0.34%)
     
  • Gold

    1,828.40
    +9.50 (+0.52%)
     
  • Silver

    24.28
    +0.19 (+0.79%)
     
  • EUR/USD

    1.2058
    -0.0020 (-0.17%)
     
  • 10-Yr Bond

    0.9340
    0.0000 (0.00%)
     
  • Vix

    20.94
    +0.37 (+1.80%)
     
  • GBP/USD

    1.3352
    -0.0071 (-0.53%)
     
  • USD/JPY

    104.6750
    +0.3590 (+0.34%)
     
  • BTC-USD

    19,117.48
    -54.26 (-0.28%)
     
  • CMC Crypto 200

    374.98
    -4.88 (-1.29%)
     
  • FTSE 100

    6,396.57
    +11.84 (+0.19%)
     
  • Nikkei 225

    26,800.98
    +13.44 (+0.05%)
     

Atara Biotherapeutics to Announce First Quarter 2020 Financial Results on Wednesday, May 6, 2020

·2 min read

Live Conference Call and Webcast at 4:30 p.m. EDT

Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases, today announced the Company will release first quarter 2020 financial results after market close on Wednesday, May 6, 2020. Following the release, the Company will host a live conference call and webcast at 4:30 p.m. EDT to discuss the Company’s financial results and provide a corporate update.

Analysts and investors can participate in the conference call by dialing (888) 540-6216 for domestic callers and (734) 385-2715 for international callers, using the conference ID 5488522. A live audio webcast can be accessed by visiting the Investors & Media – News & Events section of atarabio.com. An archived replay will be available on the Company's website for 14 days following the live webcast.

About Atara Biotherapeutics, Inc.

Atara Biotherapeutics, Inc. (@Atarabio) is a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases. Atara’s technology platform leverages research collaborations with leading academic institutions with the Company’s scientific, clinical, regulatory and manufacturing expertise. Atara’s pipeline includes tab-cel® (tabelecleucel), which is in Phase 3 development for patients with Epstein-Barr virus-associated post-transplant lymphoproliferative disease (EBV+ PTLD) as well as in earlier stage development for other EBV-associated hematologic malignancies and solid tumors, including nasopharyngeal carcinoma (NPC); T-cell immunotherapies targeting EBV antigens believed to be important for the potential treatment of multiple sclerosis; and next-generation chimeric antigen receptor T-cell (CAR T) immunotherapies. The company was founded in 2012 and is co-located in South San Francisco and Southern California. Our Southern California hub is anchored by its manufacturing facility in Thousand Oaks, California. For additional information about the company, please visit atarabio.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200430005945/en/

Contacts

INVESTORS & MEDIA:

Media
Kerry Beth Daly
Head, Corporate Communications
Atara Biotherapeutics
516-982-9328
kdaly@atarabio.com

Investors
Eric Hyllengren
Vice President, Investor Relations and Finance
Atara Biotherapeutics
805-395-9669
ehyllengren@atarabio.com